格隆汇10月17日丨根据联交所最新权益披露资料显示，2025年10月13日，恒瑞医药(01276.HK)获GIC Private Limited在场内以每股均价82.7931港元增持48.62 万股，涉资约4025.4万港元。 | 表格序號 | 大股東/董事/最高行政人員名稱作出披露的 買入 / 費出或涉及的 每股的平均價 | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | | | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | (請參聞上述 * 註 | | 有投票權股 (日 / 月 / 年) | | | | | | 份自分比 | | | | | | | | | ( %) | | | CS20251016E00296 | 486,200(L) GIC Private Limited | 1101(L) | | HKD 82.7931 | 52.018.600(L) | 20.15(L)13/10/2025 | 增持后，GIC Private Limited最新持股数目为5201.86万股，持股比例由19.96%上升至20. ...

Core Viewpoint - GIC Private Limited has increased its stake in Heng Rui Medicine (01276) by acquiring 486,200 shares at a price of HKD 82.7931 per share, totaling approximately HKD 40.254 million, resulting in a new holding of 52,018,600 shares, which represents 20.15% of the company [1] Summary by Category - **Share Acquisition** - GIC Private Limited purchased 486,200 shares of Heng Rui Medicine [1] - The acquisition price was HKD 82.7931 per share [1] - The total investment amounted to approximately HKD 40.254 million [1] - **Ownership Structure** - Following the acquisition, GIC's total shareholding in Heng Rui Medicine reached 52,018,600 shares [1] - GIC's ownership percentage in the company is now 20.15% [1]

Core Insights - The article highlights the top and bottom AH premium rates for various stocks as of October 16, with Northeast Electric (00042) leading with a premium rate of 770.97% [1] - The article also provides a detailed ranking of stocks based on their deviation values, indicating significant discrepancies between H-shares and A-shares [2] AH Premium Rate Rankings - Northeast Electric (00042) has the highest AH premium rate at 770.97%, followed by Hongye Futures (03678) at 243.57% and Zhejiang Shibao (01057) at 235.64% [1] - The lowest AH premium rates are recorded for Ningde Times (03750) at -17.41%, followed by Heng Rui Medicine (01276) at -2.37% and China Merchants Bank (03968) at 1.87% [1] Deviation Value Rankings - The top three stocks with the highest deviation values are Chenming Paper (01812) at 23.69%, Jieli Yongci (06680) at 22.33%, and Nanjing Panda Electronics (00553) at 21.48% [1] - The stocks with the lowest deviation values include Northeast Electric (00042) at -40.29%, Shanghai Electric (02727) at -24.14%, and China Southern Airlines (01055) at -12.55% [2]

Group 1 - The article highlights the top three and bottom three AH premium rates for various stocks as of October 15, with Northeast Electric (00042) leading at 770.97% and Ningde Times (03750) at -18.39% [1] - The top three stocks with the highest deviation values are Nanjing Panda Electronics (00553), Fudan Zhangjiang (01349), and Chenming Paper (01812), with values of 20.82%, 20.22%, and 16.04% respectively [1] - The bottom three stocks with the lowest deviation values include Northeast Electric (00042), Shanghai Electric (02727), and China National Foreign Trade (00598), with values of -41.76%, -28.14%, and -10.84% respectively [1] Group 2 - The top ten AH stocks by premium rate include companies like Hongye Futures (03678) and Fudan Zhangjiang (01349), with premium rates of 243.56% and 230.63% respectively [1] - The bottom ten AH stocks by premium rate feature companies such as Midea Group (00300) and Zijin Mining (02899), with premium rates of 6.25% and 10.78% respectively [1] - The article provides a detailed table of premium rates and deviation values for various stocks, indicating significant disparities between H-shares and A-shares [2]

格隆汇10月14日丨恒瑞医药(01276.HK)发布公告，2025年10月14日耗资人民币1306.63万元回购20万股A 股，回购价格每股64-67元。 ...

智通财经APP讯，恒瑞医药(01276)发布公告，该公司于2025年10月14日斥资1306.63万元人民币回购20 万股A股，每股回购价格为64-67元人民币。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) 公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2025年10月14日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | | 於香港聯交所上市 | 否 | | | 證券代號 ...

Core Insights - The article highlights the top and bottom AH premium rates for various stocks as of October 14, with Northeast Electric (00042) leading with a premium rate of 770.97% [1] - The article also discusses the deviation values of these stocks, indicating significant discrepancies between their A-shares and H-shares [1] Summary by Category Top AH Premium Rates - Northeast Electric (00042) has the highest premium rate at 770.97%, followed by Hongye Futures (03678) at 244.85% and Zhejiang Shibao (01057) at 235.03% [1] - Other notable mentions include Sinopec Oilfield Service (01033) with a premium rate of 231.58% and Andeli Juice (02218) at 231.48% [1] Bottom AH Premium Rates - The stocks with the lowest AH premium rates include Ningde Times (03750) at -19.47%, followed by Hengrui Medicine (01276) at -0.26% and China Merchants Bank (03968) at 2.62% [1] - Other companies with low premium rates include Midea Group (00300) at 8.84% and Fuyao Glass (03606) at 14.22% [1] Top Deviation Values - The stocks with the highest deviation values include Jinli Permanent Magnet (06680) at 29.10%, Nanjing Panda Electronics (00553) at 24.56%, and Dazhong Public Utilities (01635) at 22.28% [1] - Other companies with significant deviation values are Zhejiang Shibao (01057) at 17.07% and Fudan Zhangjiang (01349) at 16.81% [1] Bottom Deviation Values - Northeast Electric (00042) has the lowest deviation value at -41.76%, followed by Shanghai Electric (02727) at -9.05% and China National Foreign Trade (00598) at -8.58% [1] - Other companies with low deviation values include COSCO Shipping Energy (01138) at -7.53% and Ningde Times (03750) at -6.00% [2]

智通财经APP获悉，大和发布研报称，首次覆盖恒瑞医药(01276)H股予"持有"评级，目标价86港元。该 行指，恒瑞医药的创新药授权在行业中较为领先，因集团拥有商业化的创新药组合，研发管线中有超过 90种新分子实体，并正在发展业务拓展(BD);该行预期2025至27年的授权收入分别达41亿、29亿及10亿 元人民币。该行看好其基本面，催化剂包括国内的创新药销售增长、药物数据释出、BD交易及获授权 项目的海外进展。 ...

Company News - Yuanshan Group (00551.HK) reported a cumulative operating income of approximately $6.017 billion for the first nine months, a decrease of 1% year-on-year [2] - Baoshan International (03813.HK) recorded a cumulative operating income of 12.903 billion yuan for the first nine months, down 7.7% year-on-year [2] - Longyuan Power (00916.HK) achieved a cumulative power generation of 56,546,706 MWh in the first nine months, a decline of 0.53% year-on-year; excluding the impact of thermal power, there was a year-on-year increase of 13.81%, with wind power up 5.30% and solar power up 77.98% [2] Financial Performance - Qinhuangdao Port Co., Ltd. (03369.HK) reported a total throughput of 317 million tons for the first nine months, an increase of 5.56% year-on-year [3] - New China Life Insurance (01336.HK) expects net profit attributable to shareholders for the first three quarters to be between 29.986 billion yuan and 34.122 billion yuan, representing a year-on-year growth of 45% to 65% [3] - Jiangshan Holdings (00295.HK) reported a total power generation of approximately 238,787 MWh for the first nine months, a decrease of 4.83% year-on-year [3] - Morning News Technology (02000.HK) reported an unaudited revenue of 270 million HKD for the first nine months, down 7.6% year-on-year [3] - Dekang Agriculture and Animal Husbandry (02419.HK) sold approximately 7.5509 million pigs in the first nine months, with sales revenue of approximately 14.277 billion yuan [3] Drug Approvals and Developments - Hengrui Medicine (01276.HK) received a clinical trial approval notice for SHR-A2102, a targeted Nectin-4 antibody-drug conjugate (ADC) developed in-house; global sales for similar products are expected to reach approximately $1.949 billion in 2024 according to EvaluatePharma [3] - Hutchison China MediTech (00013.HK) plans to announce FRUSICA-2 registration study data at the 2025 European Society for Medical Oncology annual meeting [3] - CSPC Pharmaceutical Group (01093.HK) had its new drug application for Idaglutide α injection accepted by the National Medical Products Administration [3] Corporate Actions - Huazhen Medical (01931.HK) announced the acquisition of U.S. properties and the establishment of a U.S. subsidiary, ETHK BANK, to promote stablecoins and intellectual property securitization in the U.S. [3] - Lihigh Holdings (08472.HK) plans to invest 24 million HKD in cryptocurrency and commodities [3] - Hisense Home Appliances (00921.HK) and its subsidiaries subscribed to a financial product from Jingu Trust worth 1.739 billion HKD [3] Real Estate Performance - New Town Development (01030.HK) reported cumulative contract sales of 15.050 billion yuan for the first nine months, a decrease of 52.72% year-on-year [3] - Longfor Group (00960.HK) achieved total contract sales of 50.75 billion yuan in the first nine months [3] - CIFI Holdings Group (00884.HK) reported cumulative contract sales of approximately 13.06 billion yuan for the first nine months [3] - Ronshine China Holdings (03301.HK) reported contract sales of 3 billion yuan for the first nine months, down 45.3% year-on-year [3] - Yuzhou Group (01628.HK) reported cumulative sales of 4.913 billion yuan for the first nine months [3] - Yida China (03639.HK) reported contract sales of approximately 572 million yuan for the first nine months, down 24.74% year-on-year [3] Financing and Buyback Activities - Geely Automobile (00175.HK) was approved to issue debt financing instruments totaling no more than 10 billion yuan [3] - HSBC Holdings (00005.HK) repurchased 1.58 million HKD worth of shares at prices ranging from 102.2 to 103.77 HKD [3] - Xiaomi Group-W (01810.HK) repurchased 400 million HKD worth of shares at prices ranging from 47.82 to 50.55 HKD [3] - Shoucheng Holdings (00697.HK) repurchased 890 million HKD worth of shares at prices ranging from 2.21 to 2.27 HKD [3]